Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Lanvers

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Pediatric Blood & Cancer|September 11, 2012
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapyWing H Tong, Rob Pieters, Wim C J Hop, et al.
Anticancer Research|February 7, 2016
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric MalignanciesSamuel Abbou, Claudia Lanvers-Kaminsky, Estelle Daudigeos-Dubus, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 19, 2025
PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug ExposureGudrun Würthwein, Christian Siebel, Claudia Lanvers-Kaminsky, et al.
Scientific Reports|December 9, 2020
Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian CenterDaiane Keller Cecconello, Ciliana Rechenmacher, Isabel Werlang, et al.
Blood|September 24, 2011
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trialsAndrea Willer, Joachim Gerss, Thorsten König, et al.
Oncology Reports|August 4, 2005
Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivoClaudia Lanvers-Kaminsky, Barbara Winter, Susanne Koling, et al.
Leukemia & Lymphoma|September 5, 2019
Asparaginase activities during intensified treatment with pegylated <i>E. coli</i> asparaginase in adults with newly-diagnosed acute lymphoblastic leukemiaClaudia Lanvers-Kaminsky, Andreas Niemann, Maria Eveslage, et al.
Plos One|November 25, 2015
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsEstelle Daudigeos-Dubus, Ludivine Le Dret, Claudia Lanvers-Kaminsky, et al.
Therapeutic Drug Monitoring|February 6, 2020
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 StudyGudrun Würthwein, Claudia Lanvers-Kaminsky, Joachim Gerss, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocolsHans-Joachim Müller, Rita Beier, João Casimiro da Palma, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Pediatric Blood & Cancer|September 11, 2012
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapyWing H Tong, Rob Pieters, Wim C J Hop, et al.
Anticancer Research|February 7, 2016
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric MalignanciesSamuel Abbou, Claudia Lanvers-Kaminsky, Estelle Daudigeos-Dubus, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 19, 2025
PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug ExposureGudrun Würthwein, Christian Siebel, Claudia Lanvers-Kaminsky, et al.
Scientific Reports|December 9, 2020
Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian CenterDaiane Keller Cecconello, Ciliana Rechenmacher, Isabel Werlang, et al.
Blood|September 24, 2011
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trialsAndrea Willer, Joachim Gerss, Thorsten König, et al.
Oncology Reports|August 4, 2005
Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivoClaudia Lanvers-Kaminsky, Barbara Winter, Susanne Koling, et al.
Leukemia & Lymphoma|September 5, 2019
Asparaginase activities during intensified treatment with pegylated <i>E. coli</i> asparaginase in adults with newly-diagnosed acute lymphoblastic leukemiaClaudia Lanvers-Kaminsky, Andreas Niemann, Maria Eveslage, et al.
Plos One|November 25, 2015
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsEstelle Daudigeos-Dubus, Ludivine Le Dret, Claudia Lanvers-Kaminsky, et al.
Therapeutic Drug Monitoring|February 6, 2020
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 StudyGudrun Würthwein, Claudia Lanvers-Kaminsky, Joachim Gerss, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocolsHans-Joachim Müller, Rita Beier, João Casimiro da Palma, et al.
Pageof 6